Compare Blackrock Inc (BLK) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackrock Inc vs Crispr Therapeutics AG — how do they compare? Blackrock Inc trades at $1,144.15 (market cap $175.22B), while Crispr Therapeutics AG trades at $53.88 (market cap $5.17B). The key difference: Blackrock Inc is far larger — about 33.9× Crispr Therapeutics AG's market cap, and Blackrock Inc pays a 2.03% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| BLK | CRSP | |
|---|---|---|
Market Cap | $175.22B | $5.17B |
Volume | 641,547 | — |
Sector | Financials | Health |
52-Week High | $1.20K | $76.78 |
52-Week Low | $922.90 | $44.34 |
Enterprise Value | $176.32B | $3.59B |
Dividend Yield | 2.03% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
